http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3198026-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2dda62b54211f8e2448783d27fbb26fc |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2527-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2525-186 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6816 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6858 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate | 2015-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaff47793e130f9e1dd03476342209f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3854ced760c73318b325010656f41a0c |
publicationDate | 2017-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-3198026-A1 |
titleOfInvention | Method of determining pik3ca mutational status in a sample |
abstract | The invention relates to an ultra-sensitive and highly specific methodology for the detection of PIK3CA mutations in the biological samples of cancer patients that is based on a combination of allele-specific, asymmetric rapid PCR and melting analysis in a DNA sample from Circulating Tumor Cells (CTCs), cell-free DNA (cfDNA) in plasma/serum, or Formalin-Fixed Paraffin-Embedded tissues (FFPE). Using the allele-specific primers for each hotspot mutations in exons 9 and 20 (E545K and H1047R, respectively), according to the invention detection can enhance the amplification of the mutant PIK3CA allele sequence, whereas the presence of the corresponding competitive blocking unlabeled probes for each exon can avoid the non-specific amplification of the wild-type PIK3CA sequence increasing the sensitivity and the specificity of method. The mutational detection is completed with the melting curve analysis of the unlabeled probe and the DNA template of the mutant PIK3CA sequence. The evaluation of PIK3CA mutational status on CTC in peripheral blood and cfDNA in plasma/serum of cancer patients is a strategy with potential clinical applications and could have an important impact on therapeutic interventions since the presence of PIK3CA mutations is associated with response to molecular targeted therapies. |
priorityDate | 2014-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.